Outcomes of transcatheter aortic valve replacement in patients with hypertrophic cardiomyopathy: a systematic review.

4区医学

Annals of translational medicine Pub Date : 2025-02-28 Epub Date: 2025-02-25 DOI:10.21037/atm-24-41

Karsten Parker, Abdelrahman Aljadi, Uzoma N Ibebuogu

{"title":"Outcomes of transcatheter aortic valve replacement in patients with hypertrophic cardiomyopathy: a systematic review.","authors":"Karsten Parker, Abdelrahman Aljadi, Uzoma N Ibebuogu","doi":"10.21037/atm-24-41","DOIUrl":null,"url":null,"abstract":"Background: Transcatheter aortic valve replacement (TAVR) is a guideline recommended minimally invasive cardiovascular procedure used to replace severely stenosis aortic valves. Patients with severe aortic stenosis (AS) and co-existing hypertrophic cardiomyopathy (HCM), a common defect affecting the left ventricle of the heart, have been excluded from TAVR studies due to perceived challenges to optimal valve implantation in this group of patients because of the hypertrophied left ventricle that can result in an abrupt drop in afterload from a newly replaced and more efficient aortic valve. This exclusion has resulted in paucity of data on this patient population. This study aims to review outcomes in patient with HCM undergoing TAVR for severe AS.Methods: Using the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Statement, we performed a systematic literature search of published outcomes regarding TAVR in HCM patients to provide some insight in this patient population.Results: Our study showed that TAVR had significantly lower rates of in-hospital mortality, bleeding requiring a blood transfusion, invasive mechanical ventilation, acute kidney injury, vascular complications, and decreased length of stay (LOS) compared to surgical aortic valve replacement (SAVR) in our study population of 836 subjects from 11 publications. Our study is not a randomized controlled trial, which limits its generalization.Conclusions: In severe AS patients with HCM, TAVR results in better outcomes compared to surgery.","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 1","pages":"6"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921376/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of translational medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/atm-24-41","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Transcatheter aortic valve replacement (TAVR) is a guideline recommended minimally invasive cardiovascular procedure used to replace severely stenosis aortic valves. Patients with severe aortic stenosis (AS) and co-existing hypertrophic cardiomyopathy (HCM), a common defect affecting the left ventricle of the heart, have been excluded from TAVR studies due to perceived challenges to optimal valve implantation in this group of patients because of the hypertrophied left ventricle that can result in an abrupt drop in afterload from a newly replaced and more efficient aortic valve. This exclusion has resulted in paucity of data on this patient population. This study aims to review outcomes in patient with HCM undergoing TAVR for severe AS.

Methods: Using the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Statement, we performed a systematic literature search of published outcomes regarding TAVR in HCM patients to provide some insight in this patient population.

Results: Our study showed that TAVR had significantly lower rates of in-hospital mortality, bleeding requiring a blood transfusion, invasive mechanical ventilation, acute kidney injury, vascular complications, and decreased length of stay (LOS) compared to surgical aortic valve replacement (SAVR) in our study population of 836 subjects from 11 publications. Our study is not a randomized controlled trial, which limits its generalization.

Conclusions: In severe AS patients with HCM, TAVR results in better outcomes compared to surgery.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of translational medicine Multiple-

自引率

0.00%

发文量

769

期刊介绍： The Annals of Translational Medicine (Ann Transl Med; ATM; Print ISSN 2305-5839; Online ISSN 2305-5847) is an international, peer-reviewed Open Access journal featuring original and observational investigations in the broad fields of laboratory, clinical, and public health research, aiming to provide practical up-to-date information in significant research from all subspecialties of medicine and to broaden the readers’ vision and horizon from bench to bed and bed to bench. It is published quarterly (April 2013- Dec. 2013), monthly (Jan. 2014 - Feb. 2015), biweekly (March 2015-) and openly distributed worldwide. Annals of Translational Medicine is indexed in PubMed in Sept 2014 and in SCIE in 2018. Specific areas of interest include, but not limited to, multimodality therapy, epidemiology, biomarkers, imaging, biology, pathology, and technical advances related to medicine. Submissions describing preclinical research with potential for application to human disease, and studies describing research obtained from preliminary human experimentation with potential to further the understanding of biological mechanism underlying disease are encouraged. Also warmly welcome are studies describing public health research pertinent to clinic, disease diagnosis and prevention, or healthcare policy.  With a focus on interdisciplinary academic cooperation, ATM aims to expedite the translation of scientific discovery into new or improved standards of management and health outcomes practice.